Observes Tumor Treating Fields use in pleural mesothelioma patients
Collects real-life data on a device treatment in adults with pleural mesothelioma.
Plain-language title generated from the registry record
Registry title: TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
Key facts
- Where
- Alessandria and Bergamo, ItalySee the 2 sites
Where in Italy
- Azienda Ospedaliero-Universitaria di Alessandria "SS. Antonio e Biagio e C. Arrigo"Alessandria, ItalyTaking people
- Humanitas GavazzeniBergamo, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- NovoCure Ltd.
- Trial code
- NCT05538806
- Record updated
- 22 August 2025
- Original description
The purpose of this post-authorisation medical device study is to obtain real life data on the use of Tumor Treating Fields (TTFields) in patients with pleural mesothelioma in routine clinical care. Patients with pleural mesothelioma and clinical indication for TTFields treatment will be enrolled in the study after signing Informed consent to use their data and process it centrally for research purposes. The clinical indication for TTFields is one of the inclusion criteria and is defined prior to inclusion by the treating physician.Read full original descriptionShow less
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study - TIGER Meso Study
The purpose of this post-authorisation medical device study is to obtain real life data on the use of Tumor Treating Fields (TTFields) in patients with pleural mesothelioma in routine clinical care. Patients with pleural mesothelioma and clinical indication for TTFields treatment will be enrolled in the study after signing Informed consent to use their data and process it centrally for research purposes. The clinical indication for TTFields is one of the inclusion criteria and is defined prior to inclusion by the treating physician.
Inclusion: ≥ 18 years of age; Histologically confirmed pleural mesothelioma without any option of curative resection; Planned treatment with NovoTTF-200T System according to IFU and medical guidelines; Life expectancy more than 3 months at day of enrollment; Signed informed consent for use and processing of data.
Exclusion: Previous treatment with NovoTTF-200T for more than 1 week at day of enrollment.